Madrigal Pharmaceuticals, Inc. Earnings

Madrigal Pharmaceuticals, Inc.’s revenue jumped 362.03% since last year same period to $287.27Mn in the Q3 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 34.99% jump in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit fell -6.76% since last year same period to $-114.19Mn in the Q3 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated -170.07% fall in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit margin jumped 76.89% since last year same period to -39.75% in the Q3 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated -100.07% fall in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.89 - a -47.43% fall from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.89.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.